Evolving Management of EGFR Exon20+ NSCLC: Future Directions in Care
Closing out their discussion on EGFR Exon20+ non–small cell lung cancer, Joshua Sabari, MD, and Misako Nagasaka, MD, share excitement for future evolutions in the treatment paradigm.
EP: 1.Paradigm of NGS Testing in Patients With Advanced NSCLC
EP: 2.Uncommon EGFR Mutations in Advanced Non–Small Cell Lung Cancer
EP: 3.First- and Second-Line Treatment Options for EGFR Exon20+ NSCLC
EP: 4.Trial Data and Experience With Amivantamab in EGFR Exon20+ NSCLC
EP: 5.EGFR Exon20+ NSCLC: Trial Data With Mobocertinib
EP: 6.Factors in Selecting Novel Therapy for Patients With EGFR Exon20+ NSCLC
EP: 7.Advanced NSCLC: CNS Penetration With Novel EGFR TKI Therapy
EP: 8.Evolving Management of EGFR Exon20+ NSCLC: Future Directions in Care
EP: 9.Amivantamab vs Mobocertinib in Exon 20 NSCLC
EP: 10.Frontline Forum: Testing and Targeted Therapy in EGFR Exon20+ NSCLC
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
![“These results and the lack of systemic toxicity observed with [TTFields] provide patients with a promising new treatment option,” according to Joachim Aerts, MD, an investigator of the phase 3 LUNAR trial (NCT02973789).](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F7d7dfad7849391f4be3ebd2cf39c24f5369cfcd1-1200x1176.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "“These results and the lack of systemic toxicity observed with [TTFields] provide patients with a promising new treatment option,” according to Joachim Aerts, MD, an investigator of the phase 3 LUNAR trial (NCT02973789).")
